Almonertinib Plus Metronomic Oral Vinorelbine

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

Inclusion Criteria:Non-small cell lung cancer diagnosed by histopathology or cytology;Previous molecular pathology was EGFR sensitive mutation;Stage IV;ECOG score 0-2;Prior to receiving the third generation of EGFR-TKI targeted therapy, and TKI targeted therapy showed limited progress;According to RECIST1.1 standards, there are measurable or evaluable lesionsThe patient has fully understood this study and voluntarily signed a written informed consent form;The estimated survival time is more than 3 months.Exclusion Criteria:Histological or cytological confirmation of small cell lung cancer or squamous cell carcinoma at the first diagnosis;The progression of the third generation EGFR-TKI suggests histological transformation.